Európska únia - slovenčina - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

yulin hotborn medical equipment co., ltd no.1, haobang road, yulin economic development zone guangxi Čína -

Európska únia - slovenčina - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastické činidlá - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

csl behring gmbh, nemecko - Ľudský imunoglobulín anti-d (rh) - 59 - immunopraeparata

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

octapharma (ip) sprl, belgicko - Ľudský imunoglobulín anti-d (rh) - 59 - immunopraeparata

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

octapharma (ip) sprl, belgicko - Ľudský imunoglobulín anti-d (rh) - 59 - immunopraeparata

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

octapharma (ip) sprl, belgicko - normálne ľudské imunoglobulíny na intravenózne použitie - 59 - immunopraeparata

Európska únia - slovenčina - EMA (European Medicines Agency)

novartis europharm limited - omalizumab - asthma; urticaria - drogy obštrukčnej choroby dýchacích ciest, - alergické asthmaxolair je indikovaný u dospelých, dospievajúcich a detí (od 6 do.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

neovii biotech gmbh, nemecko - antitymocytový imunoglobulín (králičí) - 59 - immunopraeparata

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sanofi b.v., holandsko - antitymocytový imunoglobulín (králičí) - 59 - immunopraeparata